Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Autor:	Jennifer Le, Manjunath P. Pai, Catherine Liu, Michael J. Rybak, Thomas P. Lodise, Benjamin M. Lomaestro, Donald P. Levine, Annie Wong-Beringer, John S. Bradley, Holly D. Maples, Keith A. Rodvold, John C. Rotschafer, Bruce A. Mueller
Rok vydání:	2020
Předmět:	medicine.medical_specialty Surrogate endpoint business.industry General Medicine Guideline biochemical phenomena metabolism and nutrition medicine.disease_cause Methicillin-resistant Staphylococcus aureus Executive Summary/Guideline Patient safety Infectious Diseases Pharmacodynamics Pediatrics Perinatology and Child Health Pediatric Infectious Disease medicine book.journal Vancomycin Dosing Intensive care medicine business book medicine.drug
Zdroj:	J Pediatric Infect Dis Soc
ISSN:	2048-7207
Popis:	Background Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inhibitory concentration (AUC/MIC) has been identified as the most appropriate pharmacokinetic/pharmacodynamic (PK/PD) target for vancomycin. The 2009 vancomycin consenus guidelines recommended specific trough concentrations as a surrogate marker for AUC/MIC. However, more recent toxicodynamic studies have reported an increase in nephrotoxicity associated with trough monitoring. Methods and results This is the executive summary of the new vancomycin consensus guidelines for dosing and monitoring vancomycin therapy and was developed by the American Society of Health-Systems Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. Conclusions The recommendations provided in this document are intended to assist the clinician in optimizing vancomycin for the treatment of invasive MRSA infections in adult and pediatric patients. An AUC/MIC by broth microdilution (BMD) ratio of 400 to 600 (assuming MICBMD of 1 mg/L) should be advocated as the target to achieve clinical efficacy while improving patient safety for patients with serious MRSA infections. In such cases, AUC-guided dosing and monitoring is the most accurate and optimal way to manage vancomycin therapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c361ddbbe50d9f51edc91abb26e82f78 https://doi.org/10.1093/jpids/piaa057 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.